Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

The Sphere’s success comes as Hollywood is in a bind. Viewers’ habits have been changing over the past decade, giving way to ...

Ayala Land, Inc. (ALI) has agreed to sell its 50 percent stake in Alabang Commercial Center Corp. (ACCC), the entity that owns and operates the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals is ...

Madrigal Pharmaceuticals (MDGL) is back on investors radar after Rezdiffra s early launch exceeded expectations, putting the MASH therapy on a path toward blockbuster level sales and reshaping the ...

Madrigal Pharmaceuticals' Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination therapies for better patient outcomes. The exclusive global agreement will allow ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals ...